--- a
+++ b/clusters/3009knumclusters/clust_204.txt
@@ -0,0 +1,570 @@
+Alkaline phosphatase =< 2.5 x ULN (=< 5 x ULN for patients with documented liver involvement or bone metastases)
+Alkaline phosphatase must be within the range allowing for eligibility, must be obtained < 2 weeks prior to randomization
+Alkaline phosphatase =< 1.5 x the institutional ULN
+Alkaline phosphatase (ALK Phos) =< 2.5 x institutional ULN
+Alkaline phosphatase =< 1.5 x IULN within 28 days prior to registration
+Within 6 weeks prior to randomization: Alkaline phosphatase must be =< 2.5 x ULN for the lab
+Alkaline phosphatase =< 2 x ULN (=< 5 x ULN for patients with known liver involvement and =< 7 x ULN for patients with known bone involvement)
+Alkaline phosphatase (ALP) =< 2.5 x ULN measured within 28 days prior to randomization
+Alkaline phosphate =< 3 x normal
+Alkaline phosphatase =< 2.5 x ULN (CTCAE v 3.0 grade 0-1)
+Obtained within 28 days prior randomization: alkaline phosphatase must be =< 2.5 x ULN for the lab with the following exception: patients with documented liver metastases or bone involvement - alkaline phosphatase must be =< 5 x ULN; and
+Alkaline phosphatase =< 3 x ULN
+Alkaline phosphatase =< 1.5 x institutional ULN, within 21 days prior to registration
+Alkaline phosphatase within upper limits of institutional normal within 14 days prior to study entry
+Alkaline phosphatase =< 2 x IULN
+Patients must have alkaline phosphatase =< 2.5 x IULN within 14 days prior to registration
+Alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE grade 1)
+Alkaline phosphatase =< 2.5 x ULN (=< 5 x ULN for patients with documented liver involvement or bone metastases)
+Alkaline phosphatase =< 3X the institutional ULN
+Alkaline phosphatase =< 2.5 x institutional upper limit of normal
+Alkaline phosphatase equal or less than 1.5 times the upper limit of normal (ULN)
+AST (SGOT), ALT (SGPT) and Alkaline phosphatase 2.5 times upper limit of normal (if liver metastases are present, then 5 x ULN is allowed)
+Alkaline phosphatase ? 2.5 x ULN, unless the elevated alkaline phosphatase is due to bone metastasis.
+Adequate liver function as demonstrated by: Total bilirubin of < upper limit of normal (ULN), Aspartate transaminase (AST) and alanine aminotransferase (ALT) ?1.5 × ULN, Alkaline phosphatase (ALP) ?2.5x ULN or <5x ULN if bone metastases are present, Normal serum albumin
+Serum alkaline phosphatase =< 3 x upper limit of normal (ULN) in absence of liver or bone metastases and =< 5 x ULN in patients with documented bone or liver metastases
+Within 30 days prior to enrollment: Alkaline phosphatase equal or less than 1.5 times the upper limit of normal (ULN)
+Alkaline phosphatase ? 2.5 × ULN;
+Alkaline phosphatase =< 2 × ULN (=< 5 × ULN if considered due to tumor)
+aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP) ? 5 times the upper limit of normal (ULN)
+Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 X ULN (less than or equal to 5 X ULN if participant has liver metastases). If alkaline phosphatase is greater than 3 X ULN (in absence of liver metastases) or greater than 5 X ULN (in presence of liver metastases) AND the participant also is known to have bone metastases, the liver-specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of total alkaline phosphatase
+Alkaline phosphatase < 5 times ULN
+AST and/or ALT > 1.5 x ULN with concomitant alkaline phosphatase > 2.5 x ULN
+Alkaline phosphatase < 2.5 x the ULN or < 5 x the ULN if secondary to liver metastasis
+Serum alkaline phosphatase =< 5 x institutional ULN
+Alkaline phosphatase =< 3 × ULN
+Alkaline phosphatase > 3 ULN
+Alkaline phosphatase =< 4 times the upper limit of normal (unless clinically considered to be related to liver involvement with leukemia)
+Alkaline phosphatase =< 2.5 x ULN (or =< 5 x ULN for subjects with liver metastasis)
+Alkaline phosphatase =< 5 x upper limit of normal
+Alkaline phosphatase should be less than or equal to 2.5 x ULN (CTCAE v4.0, grade 1)
+Alkaline (Alk.) phosphatase =< 3 x ULN unless evidence of the direct liver involvement by lymphoma - then =< 5 x ULN obtained =< 14 days prior to registration
+Have an alanine aminotransferase (ALT) ?3.0 × ULN. (Note: There are no specific requirements for AST or alkaline phosphatase.)
+Alkaline phosphatase =< 2.5 x ULN (=< 5 x ULN for patients with documented liver involvement or bone metastases)
+Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase =< 2.5 x ULN, or =< 5 x ULN in subjects with liver metastases within 28 days of treatment initiation and must be independent of hematopoietic growth factor support
+alkaline phosphatase must be ? 2.5 x ULN for the lab; and
+Gamma-glutamyl transferase (GGT) alkaline phosphatase ? 2.5 × ULN.
+Alkaline phosphatase =< 2.5 x ULN; (=< 5 x ULN in case of bone metastasis)
+Alkaline phosphatase (ALP) =< 3.0 x ULN
+Alkaline phosphatase =< 2.5 times the upper limit of normal
+Alkaline phosphatase =< 2.5 x ULN, within 14 days prior to registration
+Alkaline phosphatase =< 2.5 X institutional upper limit of normal, determined within 14 days of registration
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase =< 5 x upper limit normal (ULN)
+Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Alkaline phosphatase =< 2.5 x upper limit of normal (ULN) or =< 5 X ULN if bone metastases (mets) are present
+Alkaline phosphatase (ALP) =< 5.0 x ULN, at the screening visit
+Alkaline phosphatase (ALP) ? 2.5 × ULN (? 5 × ULN if disease-related/in the case of liver metastases).
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) with alkaline phosphatase =< 2.5 x ULN OR AST and ALT =< 1.5 x ULN, with alkaline phosphatase > 2.5 x ULN
+ARM 2 - A: AST/ALT/alkaline phosphatase: =< 5 x ULN
+Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Alkaline phosphatase =< 3 x ULN =< 28 days prior to registration
+Alkaline phosphatase ? 3 x ULN or ? 5 x ULN if bone metastasis is present
+Alkaline phosphatase up to 2.5 x ULN.
+Patients with isolated elevations in alkaline phosphatase (ALP) < 5 x ULN in the presence of bony disease are not excluded from participating in the study
+Aspartate transaminase (AST) and alanine transaminase (ALT) ?2.5 x ULN for the institution, alkaline phosphatase ? 2.5 x ULN for the institution, unless bone metastasis is present in the absence of liver metastasis
+COHORT B ONLY: Obtained =< 14 days prior to registration: alkaline phosphatase =< 750 U/L
+Alkaline phosphatase =< 2.5 x ULN
+PART I: Alkaline phosphatase (Alk PO4) =< 3 x the upper limits of normal (except for patients with documented metastatic disease to bone and/or liver)
+Serum alkaline phosphatase (ALP) > 2 x ULN
+Bilirubin <= 1.5 mg/dL; ALT, AST, and alkaline phosphatase <= 3.0x the upper limit of normal
+Alkaline phosphatase =< 2 x upper limit of normal
+Alkaline phosphatase =< 2.5 x upper limit of reference range (or =< 5 x upper limit of reference range if considered to be related to liver or bone metastases by the principal investigator [PI])
+Alkaline phosphatase =< 2.5 x ULN or =< 5 x ULN if judged by the investigator to be related to liver metastases
+Alkaline phosphatase =< 2.5 x ULN with the following exception: patients with documented liver involvement or bone metastases: alkaline phosphatase =< 5 x ULN.
+Alkaline phosphatase < 3 x institutional upper limit of normal (ULN)
+Alkaline phosphatase less than 1.5 times ULN (grade 1)
+Patients with any elevated alkaline phosphatase due to bone metastasis can be enrolled
+Alkaline phosphatase >= 3 x institutional upper limit of normal (ULN)
+Alkaline phosphatase =< 3 x upper limit of normal
+STUDY TREATMENT: Alkaline phosphatase =< 2.5 × ULN within 14 days prior to the first study treatment with the following exception:\r\n* Patients with documented liver involvement or bone metastases: alkaline phosphatase =< 5 ×ULN.
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase =< 2.5 x institutional upper limit of normal
+ALT or aspartate AST > 1.5 x ULN concomitant with alkaline phosphatase > 2.5 x ULN
+Alkaline phosphatase (ALP) =< 2.5 x ULN or =< 5.0 x ULN for patients with bone metastases
+Alkaline phosphatase =< 2.5 x ULN; =< 5 x ULN for patients with documented liver involvement or bone metastases.
+Alkaline phosphatase =< 3 X the upper limit of normal (ULN)
+Alkaline phosphatase =< 2.5 times the ULN (=< 5 x ULN for patients with liver involvement)
+Bilirubin >2.0; alkaline phosphatase >5x upper limit of normal (ULN); ALT/AST >2x ULN. For patients with hepatic metastases, ALT/AST >5x ULN is exclusionary.
+AST and ALT =< 1.5 x ULN, with alkaline phosphatase > 2.5 x ULN
+Alkaline phosphatase < 2.5 × ULN
+Serum alkaline phosphatase =< 5 X ULN
+Obtained =< 14 days prior to registration: Alkaline phosphatase =< 3 x ULN
+Alkaline phosphatase =< 2.5 x ULN for the institution within 14 days of study registration
+Alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE v4.03 grade 1)
+Alkaline phosphatase =< 5 x ULN must be met during screening (within 21 days) and also prior to study drug administration on cycle 1 day 1
+Within 14 days prior to registration: Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3 × ULN (in the case of liver metastases ?5 × ULN), unless there are bone metastases, in which case liver-specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase.
+Liver function tests meeting one of the following criteria:\r\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) with alkaline phosphatase < 2.5 x ULN OR\r\n* AST and ALT < 1.5 x ULN, with alkaline phosphatase > 2.5 x ULN
+Alkaline phosphatase < 4 x ULN.
+Alkaline phosphatase =< 2.5 x ULN with the exception that patients with documented liver involvement or bone metastases: alkaline phosphatase =< 5 x ULN
+Alkaline phosphatase =< 3 x institutional upper limit of normal within 30 days of registration
+Obtained within 14 days prior to the first study treatment (cycle 1, day 1): alkaline phosphatase =< 2.5 x ULN with the following exception: 1) =< 5 x ULN in patients with documented liver metastases =< 7 x ULN in patients with documented bone metastases
+Alkaline phosphatase (alk phos) < 2.5 X ULN
+Serum alkaline phosphatase (ALP) =< UNL or =< 2.5 x upper limit of normal (ULN) in case of liver and bone metastases
+Alkaline phosphatase < 5 x upper limit of normal
+Alkaline phosphatase (ALP) > or = 5 x upper limit of normal (ULN).
+Alkaline phosphatase =< 2.5 X ULN
+Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Alkaline phosphatase must be =< 2.5 x ULN (unless elevated alkaline phosphatase clearly due to skeletal—rather than hepatic—process; eg, normal gamma-glutamyltransferase (GGT), presence of multiple bone metastases, absence of bulky and/or central liver metastases). Patients with Gilbert’s syndrome are allowed if total bilirubin =< 2 x ULN and direct bilirubin is =< ULN
+Alkaline (Alk) phosphatase < 2.5 x ULN
+Hepatic impairment, defined as alkaline phosphatase =< 2 x institutional ULN, within 21 days of initiation of protocol therapy
+Hepatic impairment, defined as alkaline phosphatase > 2 x institutional ULN, within 21 days of initiation of protocol therapy
+Alkaline phosphatase (ALP) =< 5.0 x ULN
+Alkaline phosphatase (Alk Phos) greater than 2.5 times the upper limit of normal
+Alkaline phosphatase =< 3 x ULN
+Determined within 3 weeks of treatment initiation: Alkaline phosphatase < 5 x ULN
+Bilirubin >2.0; alkaline phosphatase >5x upper limit of normal (ULN); ALT/AST >2x ULN.
+Alkaline phosphatase =< 2.5 institutional upper limit of normal of =< 5 x ULN if liver metastases are present
+Alkaline phosphatase =< 2.5 x ULN prior to biopsy
+Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver or bone involvement of their cancer)
+Within 14 days prior to the first study treatment (cycle 1, day 1): Alkaline phosphatase (ALP) =< 2.0 x ULN with the following exception:\r\n* Patients with documented liver involvement or bone metastases: ALP =< 5 x ULN
+Alkaline phosphatase =< 2.5 x ULN with the following exception:\r\n* Patients with documented liver involvement or bone metastases: alkaline phosphatase =< 5 x ULN
+FULL STUDY INCLUSION CRITERIA: Alkaline phosphatase (ALP) limit =< 2.5 x ULN (=< 5 x ULN for patients with liver involvement of their cancer)
+Alkaline phosphatase =< 2.5 x ULN (obtained within 28 days prior to first study treatment)\r\n* Subjects with documented liver or bone metastases should have alkaline phosphatase =< 5 x ULN
+Total bilirubin and alkaline phosphatase (ALP) =< 2 x ULN or =< 3 x ULN for Gilbert's disease
+Alkaline phosphatase (ALP) < 2.5 x ULN
+Alkaline phosphatase ? 2.5 x ULN within 14 days prior to the first study treatment (cycle 1, day 1) with the following exception:\r\n? Patients with documented liver involvement or bone metastases: alkaline phosphatase ? 5 x ULN
+Obtained =< 7 days prior to registration: Alkaline phosphatase < 5 x ULN
+Alkaline phosphatase =< 2.5 x normal prior to biopsy
+Direct bilirubin =< 1.5 x ULN except for i) patients with documented Gilbert’s syndrome for whom any bilirubin value is allowed and ii) for patients with asymptomatic hyperbilirubinemia (liver transaminases and alkaline phosphatase within normal range)
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase (ALP) =< 2.5 x ULN for the laboratory\r\n* Note: If ALP is > 1.5 x ULN, imaging to rule out bone and liver metastasis is required
+Alkaline phosphatase =< 2 times upper limit normal
+Alkaline phosphatase < 3 x ULN
+Alkaline phosphatase =< 2.5 x ULN with the following exception; alkaline phosphatase (ALP) =< 5 x ULN in patients with bone metastases
+Alkaline phosphatase > 2.5 x ULN
+Alkaline phosphatase > 5 X upper limits of normal (ULN)
+Alkaline phosphatase levels =< 2.5 x upper limit of normal (ULN)
+Alkaline phosphatase (ALP) =< 2.5 x ULN
+Serum alkaline phosphatase less than 2.5 times the upper limits of normal
+Alkaline phosphatase =< 2.5 x ULN unless bone metastases present
+Alkaline phosphatase (ALP) < 2.5 x ULN (3 x ULN for subjects on chronic anticonvulsive therapies).
+Alkaline phosphatase =< to 2.5 x ULN
+Alkaline phosphatase =< 2.5 X ULN, unless bone metastasis is present (< 5 X ULN) in the absence of liver metastasis
+Alkaline phosphatase =< 2.5 x ULN (=< 5 x ULN if bone or liver metastases present)
+Alkaline phosphatase (ALP) =< 5.0 x ULN
+Alkaline phosphatase ? 2.5 x ULN (? 5.0 x ULN if bone or liver metastases present)
+Alkaline phosphatase =< 2.5 x upper limit (UL)
+Alkaline phosphatase < 5 x ULN obtained =< 7 days prior to registration
+Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Alkaline phosphatase =< 2.5 x institutional ULN obtained within 14 days of first treatment
+For subjects without extensive bone metastases: alkaline phosphatase levels < 2.5 x ULN
+Alkaline phosphatase (Alp) =< 2.5 x upper limit of normal (ULN)
+Alkaline phosphatase (ALP) =< 2 x ULN
+CAPMATINIB INCLUSION CRITERIA: Alkaline phosphatase (ALP) =< 5 x ULN
+CERITINIB INCLUSION CRITERIA: Alkaline phosphatase (ALP) =< 5 x ULN
+REGORAFENIB INCLUSION CRITERIA: Alkaline phosphatase (ALP) =< 2.5 x ULN if no liver metastases are present; =< 5 x ULN if bone or liver metastases are present
+PHASE I: Alkaline phosphatase (ALP) < 2.5 x ULN
+Alkaline phosphatase =< 2.5 x ULN, unless elevation is thought to be due to hepatic infiltration by the hematologic malignancy
+Alanine aminotransaminase (ALT), Aspartate aminotransaminase (AST) or alkaline phosphatase (ALP) > 2.5 ULN without hepatic metastases or ALT, AST or ALP > 5 ULN with hepatic metastases
+Adequate hepatic function: bilirubin ?1.5 x upper limit of normal (ULN), AST ?2.5 x ULN, ALT ?2.5 x ULN, alkaline phosphatase (liver fraction) ?2.5 x ULN
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase (ALP) =< 5.0 x ULN
+Alkaline phosphatase (Alk phos) =< 5 X ULN
+Alkaline Phosphatase less than 2.5 x ULN (CTCAE Grade 1)
+Alkaline phosphatase (liver fraction) =< 2.5 X ULN; if AST or ALT is > 2.5 X ULN, then liver fraction of alkaline phosphatase should be =< 2.5 X ULN
+Alkaline phosphatase < 5 x upper limit of normal (ULN)
+Alkaline phosphatase =< 2 x upper limit of normal, unless proven to be due to disease involvement
+Alkaline phosphatase < 2.5 upper limit of normal (ULN) (< 10 x ULN in presence of bone metastases) within 14 days of study entry
+Alkaline phosphatase =< 2.5 x ULN for the laboratory (=< 5 x ULN for patients with cancer involving the liver and/or bone)
+Alkaline phosphatase > 2.5 x ULN
+ADDITIONAL CRITERIA FOR STUDY CONTINUATION: Alkaline phosphatase (alk phos) =< 5 X upper level of normal
+Serum glutamic-oxaloacetic transaminase (SGOT) and alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE v4 grade 1)
+Alkaline phosphatase (AP) ? 2.5 x ULN, unless considered due to organ leukemic involvement;
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) with alkaline phosphatase =< 2.5 x ULN OR AST and ALT =< 1.5 x ULN, with alkaline phosphatase > 2.5 x ULN
+Alkaline phosphatase < 2.5 x upper limit of normal
+Alkaline phosphatase > 2.5 x the ULN, there is no upper limit if bone metastasis is present in the absence of liver metastasis
+Alkaline phosphatase (ALP) =< 3 x ULN; if ALP is > 3 x ULN, gamma glutamyltransferase (GGT) must be checked and be =< 3 x ULN (must be within 7 days of MLA)
+Alkaline phosphatase (alk phos) < 2.6 x ULN
+Alkaline phosphatase (ALP) =< 5.0 x ULN
+Alkaline phosphatase =< 3 times the upper limit of normal
+Alkaline phosphatase =< 1.5 x ULN, obtained =< 14 days prior to registration
+To commence third line docetaxel, patients must have grade 2 or less neuropathy from prior oxaliplatin treatment; also bilirubin > upper limit of normal (ULN), or AST and/or ALT > 1.5 x ULN concomitant with alkaline phosphatase > 2.5 x ULN are not eligible for docetaxel therapy
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase < 5 x ULN
+Alkaline phosphatase < 3 x upper limit of normal (ULN)
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase < 2 x upper limit of normal
+Alkaline phosphatase < 2.5 times the upper limit of normal
+Alkaline phosphatase < 5 times the upper limit of normal
+Alkaline phosphatase =< 2.5 ULN
+Alkaline phosphatase > 2.5 x ULN
+Alkaline phosphatase < 5 x ULN
+Alkaline phosphatase < 2.5 x ULN
+Serum alkaline phosphatase =< 5 x ULN
+Alkaline phosphatase < 2 upper limit of normal (ULN)
+Alkaline phosphatase less than 1.5 x upper limit of normal
+Alkaline phosphatase =< 3 x ULN (in the case of liver metastases, =< 5 x ULN)
+Alkaline phosphatase < 2.5 times normal
+Alkaline phosphatase =< 3 x ULN (=< 5 x ULN with liver involvement of their cancer)
+Alkaline (Alk) phosphatase (Phos) =< 5 x upper limit of normal
+Alkaline phosphatase must be =< 4 x the institutional upper limit of normal (ULN)
+Alkaline phosphatase < 5 x ULN
+Alkaline phosphatase =< 5 x the upper limit of normal; serum bilirubin > 2.0 is acceptable in the setting of known Gilbert’s syndrome
+Alkaline phosphatase =< 2 x ULN or considered not clinically significant
+Serum alkaline phosphatase less than 2.5 times the upper limits of normal within 7 days prior to starting treatment in the absence of liver metastasis; in the presence of liver metastasis serum alkaline phosphatase less than or equal to 5.0 times the upper limits of normal within 7 days prior to starting treatment
+Bilirubin, aspartate aminotransferase (AST), alkaline phosphatase (ALK) =< 2 x normal
+Aspartate aminotransferase (AST) and alkaline phosphatase < 5 x upper limit of normal
+AST and alkaline phosphatase < 5 x upper limit of normal
+Alkaline phosphatase (ALP) < 5 x upper limit of normal
+Alkaline phosphatase (ALP) < 5 x normal
+Alkaline phosphatase (ALP) levels > 2.5 × ULN.
+Obtained =< 14 days prior to registration: Alkaline phosphatase =< 750 U/L
+Alkaline phosphatase < 4 times the upper limit of institutional normal
+Alkaline phosphatase ?2.0×ULN.
+AST (SGOT), ALT (SGPT) and Alkaline phosphatase > 2.5 times ULN
+Alkaline phosphatase must be no more than 2.5 times upper limit of normal unless due to disease involvement of the liver
+Hepatic function: total bilirubin ? 1.5 x ULN (Common Terminology Criteria for AEs [CTCAE] v4.0 grade 1) except patients with Gilbert's disease (up to 5.0 mg/dL). Aspartate aminotransferase (AST) and alkaline phosphatase ? 2.5 x ULN.
+Alkaline phosphatase ? 2.5 × ULN (? 5 ± ULN for patients with documented liver involvement or bone metastases)
+Hepatic: bilirubin < 1.5 times the upper limit of normal (ULN); alkaline phosphatase (AP), aspartate transaminase (AST), and alanine transaminase (ALT) < 3.0 x ULN (AP, AST, and ALT < 5 x ULN is acceptable if the liver has tumor involvement).
+Alkaline phosphatase ?5 x ULN
+ORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Alkaline phosphatase < 2 x ULN
+HPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Alkaline phosphatase < 2 x ULN
+Alkaline phosphatase < 2.5 X ULN
+Within 14 days prior to the first study treatment (cycle 1, day 1): Alkaline phosphatase =< 2.5 x ULN with the following exception: Patients with documented bone metastases: alkaline phosphatase =< 5 x ULN.
+Alkaline phosphatase level =< upper limit of normal (ULN)
+Within 14 days prior to first dose of study drug treatment: Alkaline phosphatase (ALP) =< 3 x ULN with the following exceptions:\r\n* Patients with documented liver or bone metastases: ALP =< 5 x ULN
+Alkaline phosphatase =< 3 X ULN unless due to direct lymphoma involvement, and then =< 5 X ULN
+Alkaline phosphatase < 5 times upper limit of normal
+Alkaline phosphastase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Alkaline phosphatase < 252 u/L
+Alkaline phosphatase =< 2.5 x ULN, obtained within 14 days prior to the first study treatment (cycle 1, day 1) with the following exception:\r\n* Patients with documented liver or bone metastases may enroll with alkaline phosphatase =< 5 x ULN
+Alkaline phosphatase < 2.0 x ULN
+Alkaline phosphatase < 2.0 x ULN (if liver or bone disease are present, < 3.0 x ULN)
+Alkaline phosphatase must be =< 3 x ULN for the lab within 28 days before randomization
+Alkaline phosphatase =< 2 x ULN (=< 5 x ULN for patients with known liver involvement and =< 7 x ULN for patients with known bone involvement)
+Performed within 14 days prior to study: Alkaline phosphatase < 3 times the upper limits of the institutional normal
+Alkaline phosphatase =< 2 x ULN (=< 5 x ULN for patients with documented liver involvement or bone metastases)
+Alkaline phosphatase (ALP) < 3 x ULN
+Alkaline phosphatase (ALK Phos) =< 2.5 X institutional upper limit of normal
+DOSE ESCALATION COHORT: Alkaline phosphatase (ALP) ? 2.5 X ULN
+Alkaline phosphatase =< 4 x institutional upper limit of normal (IULN)
+Alkaline phosphatase < 3 times upper limit of institutional normal
+Alkaline phosphatase (ALP) > 250 U/L
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline (Alk) phosphatase =< 5 x upper limit of normal
+Alkaline phosphatase > 3 x normal
+Alkaline phosphatase (ALK Phos) < 2.5 x ULN
+Within 14 days of registration: Alkaline phosphatase =< 5 x upper limit of normal
+Alkaline phosphatase =< 2.5 x institutional upper limit of normal
+Alkaline phosphatase limit =< 2.5 x ULN (=< 5.0 x ULN for subjects with intrahepatic involvement of their cancer)
+Alkaline phosphatase =< 2.5 x ULN with the following exception: \r\n* Patients with documented liver involvement or bone metastases: \r\n** Alkaline phosphatase =< 5 x ULN
+Alkaline phosphatase =< 3 X institutional upper limit of normal
+Alkaline phosphatase =< 2.5 x ULN; if liver involvement, alkaline phosphatase =< 5.0 x ULN
+Alkaline phosphatase =< 2.5 x ULN for the institution
+Alkaline phosphatase must be =< 2.5 x ULN for the lab
+Alkaline phosphatase and AST may not both be > the ULN; for example, if the alkaline phosphatase is > the ULN but =< 2.5 x ULN, the AST must be =< the ULN; if the AST is > the ULN but =< 1.5 x ULN, the alkaline phosphatase must be =< ULN; Note: If alanine aminotransferase (ALT) is performed instead of AST (per institution's standard practice), the ALT value must be =< 1.5 x ULN; if both were performed, the AST must be =< 1.5 x ULN
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase =< 2 x ULN (=< 5 x ULN for patients with known liver involvement and =< 7 x ULN for patients with known bone involvement)
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase =< 3 X institutional upper limit of normal
+Serum alkaline phosphatase < 3 times the upper limit of normal (ULN), unless due to liver or bone involvement by HL; under these circumstances, serum alkaline phosphatase must be < 5 x ULN
+Alkaline phosphatase =< 2.5 x upper limit of normal unless bone metastasis are present in the absence of liver metastases
+Alkaline phosphatase less than or equal to 2.5 x ULN (CTEP CTCAE version 4.0, grade 1)
+Alkaline phosphatase =< 2.5 x ULN
+No history of severe prior or ongoing chronic liver disease; alkaline phosphatase < 5 x upper limit of normal
+Alkaline phosphatase >= 2 x institutional ULN, within 21 days of initiation of protocol therapy
+Alkaline phosphatase =< 2.5 times the upper limit of normal in the absence of liver metastasis; alkaline phosphatase < 5.0 times ULN in the presence of liver metastasis
+Alkaline phosphatase =< 3.0 x ULN; up to 5 x ULN is acceptable if due to bone metastases in the absence of liver metastases
+Alkaline phosphatase ?2.0 x ULN or ?5 x ULN in case of bone metastasis and/or hepatic metastasis
+Inadequate organ function per protocol-specified total bilirubin, AST and ALT, creatinine clearance and alkaline phosphatase.
+Alkaline phosphatase =< 2.5 x upper limit of normal (ULN); patients with hepatic and/or bone metastases: alkaline phosphatase =< 5 x ULN
+Alkaline phosphatase >= 2 x ULN
+Alkaline phosphatase =< 2 x IULN be obtained within 42 days prior to registration
+Alkaline phosphatase <3.0 x ULN or ?5.0 x ULN if liver or bone metastases present
+Alkaline phosphatase =< 1.5 x ULN (institutional)
+Alkaline phosphatase ? 5 x ULN
+Alkaline phosphatase =< 2.5 x ULN for the institution
+Alkaline phosphatase less than or equal to 2.5 x ULN
+AST(SGOT), ALT(SGPT), or alkaline phosphatase (ALP) ? 2.5 x ULN.
+Alkaline phosphatase levels ? 2.5 × ULN (? 5 × ULN in subjects with liver metastasis)
+Alkaline phosphatase greater than 2.5 x ULN (CTCAE v4.0 grade 1) (if known hepatic metastases alkaline phosphatase may be =< 5 x ULN)
+Alkaline phosphatase* less than or equal to 2.5 x ULN
+* Patients with a history of Gilbert’s syndrome may be eligible provided total bilirubin is less than or equal to 1.5 x ULN and the AST, ALT, and alkaline phosphatase meet the criteria detailed
+Alkaline (Alk.) phosphatase =< 3 x ULN unless evidence of the direct liver involvement by lymphoma – then =< 5 x ULN
+Alkaline phosphatase =< 1.5 UNL
+alkaline phosphatase must be less than or equal to 2 x ULN; and
+alanine transaminase, aspartate aminotransferase and alkaline phosphatase ?3 × ULN or <5 × ULN in cases of liver involvement
+Alkaline phosphatase =< 2.5 x upper limit of normal
+Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Alkaline phosphatase < 5 x ULN
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase =< 3 x institutional normal
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) =< 2.5 x upper limit of normal (ULN), obtained within 14 days prior to initiation of study treatment, with the following exceptions: patients with documented liver metastases: AST and ALT =< 5 x ULN; patients with documented liver or bone metastases: alkaline phosphatase (ALP) =< 5 x ULN
+Alkaline phosphatase (ALP) ? 3.0 × ULN (< 5 × ULN if isolated ALP increase, i.e., without ALT/AST or bilirubin increase).
+Alkaline phosphatase ?2.0×ULN
+Alkaline phosphatase <3.0 x ULN or ?5.0 x ULN if liver or bone metastases present
+Alkaline phosphatase limit ? 2.5 x ULN
+Alkaline phosphatase less than or equal to 3 x ULN
+Alkaline phosphatase (ALP) >5 xULN
+Alkaline phosphatase =< 5 X upper limit of normal (ULN)
+Alkaline phosphatase < 2 x upper limit of normal, or considered not clinically significant by the study doctor or designee
+Alkaline phosphatase less than or equal to 2.5 x ULN
+Alkaline phosphatase < or equal to 4 x ULN if not related to leukemic disease
+Alkaline phosphatase (ALP) =< 2.5 x ULN unless considered tumor-related
+Alkaline phosphatase (ALP) =< 2.5 x ULN unless considered tumor related
+Alkaline phosphatase (ALP) =< 2.5 x ULN unless considered tumor related
+Participant has adequate hepatic function [bilirubin within normal limits (WNL), aspartate transaminase (AST) and alanine transaminase (ALT) ? 2.5 times the upper limit of normal (ULN), or ? 5.0 times the ULN if the transaminase elevation is due to liver metastases, and alkaline phosphatase ? 5.0 times the ULN]
+Alkaline phosphatase ? 2.5 x ULN
+Alkaline phosphatase < 2.0 x ULN (if liver or bone metastases are present, < 3.0 x ULN)
+Within 14 days of enrollment: Alkaline phosphatase =< 2.5 x ULN for the institution\r\n* For patients in the metastatic cohort with documented liver or bone metastases cohort with documented liver or bone metastases: alkaline phosphatase =< 5 x ULN
+Alkaline phosphatase within 3 times the upper limits of normal
+Alkaline phosphatase within 5 times ULN
+Alkaline phosphatase ? 5X ULN
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Alkaline phosphatase =< 3 x ULN (=< 5 x ULN if liver or bone involvement)
+Obtained =< 7 days prior to registration:\r\nAlkaline phosphatase =< 3 x ULN
+Alkaline phosphatase < 2 x ULN (if known liver or bone disease)
+Alkaline phosphatase (ALP) =< 2.5 x ULN (within 7 days prior to registration)
+Alkaline (Alk.) phosphatase =< 3 x ULN
+Alkaline phosphatase: ? 2.5 x ULN
+Alkaline phosphatase =< 2.5 x ULN obtained =< 14 days prior to registration
+Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Alkaline phosphatase > 3 x institutional ULN, within 21 days of initiation of protocol therapy
+Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for patients with liver involvement of their cancer) (obtained =< 7 days prior to randomization)
+Alkaline phosphatase =< 3 x ULN
+Alkaline phosphatase (AP) =< 2.0 x ULN
+Alkaline phosphatase < 2 X institutional ULN
+Alkaline phosphatase < 2.5 x ULN
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase < 5 x upper limit normal (ULN)
+Alkaline phosphatase =< 5 x ULN
+Alkaline phosphatase =< 3 times the institutional upper limit of normal
+Alkaline phosphatase =< 5.0 x ULN
+Alkaline phosphatase =< 1.5 x IULN
+Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Alkaline phosphatase (ALP) limit < 2.5 x ULN or =< 5.0 x ULN if liver metastases are present
+Alkaline phosphatase =< 2.5 x ULN; if bone metastasis is present in the absence of liver metastasis then =< 5 x ULN
+Alkaline phosphatase < 2.5 times institutional upper normal limit (unless due to disease involvement of the liver or bone marrow)
+Alkaline phosphatase < 5 x ULN
+Within 14 days of registration: Alkaline phosphatase =< 2.5 × institutional upper limit of normal
+Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Alkaline phosphatase =< 3 X the upper limit of normal (ULN)
+Alkaline phosphatase ? 2.5 times ULN (? 5 times ULN for patients with liver metastases);
+Alkaline phosphatase >= 2.5 times ULN
+If bone metastases are present and liver function is otherwise considered adequate by the Investigator then elevated alkaline phosphatase (ALP) will not exclude the patient.
+Alkaline phosphatase > 3 x ULN
+Alkaline phosphatase > 2 x institutional ULN
+Obtained within 14 days prior to the first study treatment (cycle 1, day 1); alkaline phosphatase ? 2.5 x ULN with the following exception:\r\n* Patients with documented liver involvement or bone metastases: alkaline phosphatase ? 5 x ULN
+Alkaline phosphatase (Alp) =< 2.5 x ULN
+Alkaline phosphatase =< 2.5 x ULN
+Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) less than or equal 3 x ULN (less than or equal 5 x ULN if subject has liver metastases). If alkaline phosphatase is greater than 3 x ULN (in absence of liver metastases) or greater than 5 x ULN (in presence of liver metastases) AND the subject also is known to have bone metastases, the liver-specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of total alkaline phosphatase.
+Alkaline phosphatase < 3 times normal
+Serum alkaline phosphatase should be =< 1.5 x institutional ULN
+Alkaline phosphatase (ALP) =< 3 x ULN; if ALP is > 3 x ULN, gamma glutamyl transpeptidase (GGT) must be checked and be =< 3 x ULN (must be within 7 days of MLA)
+Alkaline phosphatase (Alk Phos) =< 2.5 x ULN
+Alkaline (Alk) phosphatase < 2.5 x ULN
+Obtained =< 7 days prior to registration: Alkaline phosphatase =< 3 x ULN
+Alkaline phosphatase (AP) =< 3 x the ULN or =< 5 × the ULN in the presence of known liver metastases
+Alkaline phosphatase >= 3 x ULN
+Patient has poor liver function (> 2.5 times normal of alkaline phosphatase [Alk phos]) suggestive of cirrhosis or steatohepatitis
+Alkaline phosphatase =< 2.5 times upper limit of normal (unless due to disease involvement of the liver or bone marrow)
+Alkaline phosphatase (AP) =< 3 x institutional upper limit of normal
+Alkaline phosphatase =< 2.5 x upper limit of normal (ULN)
+Direct bilirubin ? 1.5 x ULN except for i) patient with documented Gilbert's syndrome for whom any bilirubin value is allowed and ii) for patients with asymptomatic hyperbilirubinemia (liver transaminases and alkaline phosphatase within normal range)
+Alkaline phosphatase ? 2.5 x ULN
+Alkaline phosphatase > 2.5 times upper normal limit (unless due to chronic GVHD)
+Alkaline phosphatase (ALP) =< 2.5 x ULN unless considered tumor related
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase =< 2.5 X ULN
+Alkaline phosphatase =< 2.5 x ULN for the institution
+Alkaline phosphatase =< 2.5 x ULN, CTCAE grade 1
+Alkaline phosphatase =< 2.5 x institutional upper limit normal
+Alkaline phosphatase < 2.5 x ULN
+Alkaline phosphatase =< 2.5 x normal prior to biopsy
+Alkaline phosphatase no greater than 1.5 times ULN
+Alkaline phosphatase =< 2.5 x ULN; unless elevated secondary to lymphoma involvement of the liver
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase =< 2.5 times upper limit of normal
+Adequate liver functions: AST and ALT =< 3xULN, alkaline phosphatase =< 3.0x ULN, except if attributed to tumor, and bilirubin =< 2xULN.
+For subjects without extensive bone metastases: alkaline phosphatase levels =< 2.5 x ULN
+For subjects with extensive bone metastases: alkaline phosphatase levels =< 5 x ULN
+Alkaline phosphatase =< 3 x ULN (=< 5 x ULN with liver involvement of their cancer)
+Alkaline phosphatase less than or equal to 2.5 x ULN
+Alkaline phosphatase values within the institutional ULN
+Alkaline phosphatase =< 2.5 x ULN (=< 5 x ULN for patients with documented liver involvement or bone metastases)
+Alkaline phosphatase =< 2.5 x ULN (obtained within 14 days prior to the first study treatment [course 1, day 1]) with the following exception:\r\n* Patients with documented liver involvement or bone metastases: alkaline phosphatase =< 5 x ULN
+Alkaline phosphatase limit <2.5 x ULN (<5 x ULN for subjects with liver involvement of their cancer)
+Alkaline phosphatase ? 2.5 x upper limit of normal (ULN)
+Gamma-glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH), and alkaline phosphatase =< 2.5 x institutional ULN
+Alkaline phosphatase =< 2.5 X ULN
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase (Alp) =< 2.5 x ULN
+Alkaline phosphatase =< 2.5 x normal limits
+Alkaline phosphatase less than 10 times the upper limit of normal (unless due to active myositis)
+Alkaline phosphatase < 3 times the upper limit of laboratory normal
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase =< 3 times upper limit of laboratory normal
+Alkaline phosphatase < 2.5 x ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and alkaline phosphatase must be within the eligible; in determining eligibility, the more abnormal of the two values (AST or ALT) should be used; patients with alkaline phosphatase elevation secondary to the bony metastases rather than liver dysfunction may proceed with treatment on protocol after discussion with the principal investigator
+Alkaline phosphatase =< upper limit of normal (ULN) and AST or ALT =< ULN eligible
+Alkaline phosphatase > 1 x ULN but =< 2.5 x ULN and AST or ALT =< ULN eligible
+Alkaline phosphatase > 2.5 x ULN but =< 5 x ULN and AST or ALT =< ULN eligible
+Alkaline phosphatase > 5 x ULN and AST or ALT =< ULN ineligible
+Alkaline phosphatase =< ULN and AST or ALT > 1 x ULN but =< 1.5 x ULN eligible
+Alkaline phosphatase > 1 x ULN but =< 2.5 x ULN and AST or ALT > 1 x ULN but =< 1.5 x ULN eligible
+Alkaline phosphatase > 2.5 x ULN but =< 5 x ULN and AST or ALT > 1 x ULN but =< 1.5 x ULN ineligible
+Alkaline phosphatase > 5 x ULN and AST or ALT > 1 x ULN but =< 1.5 x ULN ineligible
+Alkaline phosphatase =< ULN and AST or ALT > 1.5 x ULN but =< 5 x ULN eligible
+Alkaline phosphatase > 1 x ULN but =< 2.5 x ULN and AST or ALT > 1.5 x ULN but =< 5 x ULN ineligible
+Alkaline phosphatase > 2.5 x ULN but =< 5 x ULN and AST or ALT > 1.5 x ULN but =< 5 x ULN ineligible
+Alkaline phosphatase > 5 x ULN and AST or ALT > 1.5 x ULN but =< 5 x ULN ineligible
+Alkaline phosphatase =< ULN and AST or ALT > 5 x ULN ineligible
+Alkaline phosphatase > 1 x ULN but =< 2.5 x ULN and AST or ALT > 5 x ULN ineligible
+Alkaline phosphatase > 2.5 x ULN but =< 5 x ULN and AST or ALT > 5 x ULN ineligible
+Alkaline phosphatase > 5 x ULN and AST or ALT > 5 x ULN ineligible
+Alkaline phosphatase (ALP) ?5 × ULN (except for subjects with hepatomegaly and isozymes specific to liver, rather than bone)
+Alkaline phosphatase levels ? 2.5 × ULN (? 5 × ULN in subjects with liver metastasis)
+Alkaline phosphatase less than or equal to 2.5 x upper limit of normal, CTCAE v 4.0 grade 1
+Alkaline phosphatase (ALP) < 3 x UNL
+Alkaline phosphatase =< 2.5 x upper limit of normal (ULN)
+Subjects must have adequate liver function assessed by: total bilirubin <= 1.0 x upper limit of normal (ULN), aspartate aminotransferase (ALT) <= 3.0 x ULN (CTCAE Grade <=1) or, if receiving BAY1143269 in combination with IV docetaxel, AST and ALT <=1.5 x ULN if concomitant with alkaline phosphatase increase >2.5 x ULN
+Alkaline phosphatase =< 5.0 times the upper limit of normal unless hepatic dysfunction is related to liver involvement with disease
+Alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE v4.0 grade 1)
+Hepatic: Bilirubin ? 2.5 mg/dL (except in the case of Gilbert's syndrome or ongoing hemolytic anemia); and ALT, AST and Alkaline Phosphatase ? 5 × ULN.
+Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver or bone involvement of their cancer)
+Alkaline phosphatase < 3 x ULN
+Alkaline phosphatase =< 2.5 X upper limit of normal
+Alkaline phosphatase =< 1.5 x upper limit of normal
+Alkaline phosphatase =< 2 X ULN
+Alkaline phosphatase (hepatic) > 3 times the upper normal limit
+Alkaline phosphatase =< 2.5 times ULN
+Alkaline phosphatase ? 2.5 times the ULN
+Alkaline phosphatase =< 2.5 x ULN for the institution
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase =< 2.5 x IUNL
+Alkaline phosphatase (AP) must be within the range allowing for eligibility, as follows:\r\n* =< ULN\r\n* =< 2.5 x ULN\r\n* =< 5 x ULN
+Alkaline Phosphatase =< 2 x ULN (=< 5 x ULN for patients with known liver involvement and =< 7 x ULN for patients with known bone involvement)
+Serum alkaline phosphatase ? 3x ULN (upper limit of normal)in the absence of liver or bone metastases or ?5 ULN(in patients with documented bone or liver metastases)
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase =< 3.0 x ULN; if liver involvement, alkaline phosphatase =< 5.0 x ULN
+Serum alkaline phosphatase less than 2.5 times the upper limits of normal
+Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) <=3*ULN unless there are bone metastases, in which case liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase. ALT and AST <= 5*ULN if participant has liver metastases.
+Alkaline phosphatase must be =< 2.5 x ULN for the lab
+Alkaline phosphatase and AST/ALT may not both be > the ULN; for example, if the alkaline phosphatase is > the ULN but =< 2.5 x ULN, then the AST/ALT must be =< the ULN; if the AST/ALT is > the ULN but =< 1.5 x ULN, then the alkaline phosphatase must be =< ULN
+Patients with AST/ALT or alkaline phosphatase > ULN must have liver imaging that does not demonstrate metastatic disease
+Alkaline phosphatase (ALP) < 5 x upper limit of normal
+Alkaline phosphatase above 2.5X the ULN
+Alkaline phosphatase =< 5 x UNL
+Hepatic function: total bilirubin ? 1.5 x ULN; ALT and AST ? 3 x ULN; alkaline phosphatase ? 2.5 x ULN
+Alkaline phosphatase (ALP) =< 2.5 x ULN, with the following exceptions: patients with documented liver or bone metastases: ALP =< 5 x ULN
+Alkaline phosphatase (ALP) < 5 x ULN
+Alkaline phosphatase of =< 2 ULN
+Alkaline phosphatase limit =< 2.5 x ULN
+Alkaline phosphatase =< 2.5 x upper limit of normal (ULN)
+Alkaline phosphatase (Alk phos) =< 3.0 x ULN
+Alkaline phosphatase =< 2.0 x ULN; if bone or liver metastases are present, =< 5 x ULN
+Alkaline phosphatase =< 2 x upper limit of normal
+Alkaline phosphatase limit ? 2.5 x ULN (? 5 x ULN for subjects whose cancer involves their liver).
+Alkaline phosphatase =< to 2.5 x ULN
+Alkaline phosphatase =< 2.5 x ULN (unless bone metastasis is present in the absence of liver metastasis, in which case 3.0 x ULN would be acceptable)
+Alkaline phosphatase =< 5 x institutional ULN obtained =< 7 days prior to registration
+Part 2 only: plasma total bilirubin <= ULN; ALT and/or AST <= 1.5 X ULN concomitant with alkaline phosphatase <= 2.5 X ULN.
+Part 2 only: Patients with plasma total bilirubin > ULN; ALT and/or AST > 1.5 X ULN concomitant with alkaline phosphatase > 2.5 X ULN.
+Alkaline phosphatase =< 2.5 × ULN (patients with hepatic and/or bone metastases: alkaline phosphatase =< 5 × ULN)
+Liver: hepatomegaly on physical exam with elevated alkaline phosphatase > 1.5 x ULN
+Alkaline phosphatase ? 5 x ULN
+Alkaline phosphatase < 2.5 x ULN
+Alkaline phosphatase =< 2.5 x ULN
+Aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP) ? 5 times the upper limit of normal (ULN)
+Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Alkaline phosphatase =< 2.5 x ULN; except for patients with hepatic and/or bone metastases: alkaline phosphatase =< 5 x ULN
+Alkaline phosphatase < 2 x ULN (< 5 x ULN in subjects whom the PI and sponsor agree that clinical data suggest extrahepatic source of elevation)
+Alkaline phosphatase (AP) =/< 2.5 x ULN
+Alkaline phosphatase =< 3 x ULN, unless evidence of direct liver involvement by lymphoma, then =< 5 x ULN
+Patients enrolled without hepatic dysfunction must have laboratory test results for total bilirubin of less than the ULN, alkaline phosphatase (ALP) <=1.5x the ULN, and AST and ALT of <=the ULN.
+Alkaline phosphatase > 1.5 x ULN (unless due to lymphoma or a non-malignant, non-hepatic cause such as Paget's disease)
+Alkaline phosphatase > 2 x upper limits of normal (ULN)
+Alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE grade 1)
+Alkaline phosphatase =< 2.5 X upper limit of normal
+Alkaline phosphatase < 2 X upper limit of normal
+Alkaline phosphatase =< 1.5 x ULN
+Alkaline phosphatase =< 2.5 x upper limit of normal (< 5 X ULN for subjects with bone or liver metastasis)
+Alkaline phosphate =< 2.5 x ULN (within four weeks prior to the study)
+Alkaline phosphatase < 2 times ULN, unless arising from bone
+Bilirubin and Alkaline phosphatase (ALP) =< 2 x ULN
+Alkaline phosphatase =< 5 x ULN
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase =< 2.5 x upper limit of normal (ULN)
+Alkaline phosphatase limit =< 2.5 x ULN
+Alkaline phosphatase < 2 times ULN, unless arising from bone
+Alkaline phosphatase less than or equal to 2.5 x ULN
+Alkaline phosphatase (ALP) =< 5.0 x ULN
+Alkaline phosphatase < 3 x upper limit of normal
+Alkaline phosphatase limit =< 2.5 x ULN
+Alkaline phosphatase =< 3 x ULN unless due to direct lymphoma involvement, and then =< 5 x ULN
+Serum alkaline phosphatase < 2 x ULN, or considered not clinically significant by the study doctor or designee
+Alkaline phosphatase (hepatic) > 3 times the upper normal limit
+Alkaline phosphatase < 2.5 X institutional upper limit of normal
+Alkaline phosphatase =< 5x upper limit of normal
+Alkaline phosphatase ? 2.5 times ULN (? 5 times ULN for patients with liver metastases);
+Alkaline phosphatase =< 1.5 x upper limit of normal (ULN).
+Alkaline phosphate > 1.5 x ULN
+Obtained =< 30 days prior to registration: Alkaline phosphatase =< 3 x the institutional upper limit of normal
+Patients with plasma alkaline phosphatase greater than 190 IU/dL
+Alkaline phosphatase =< 2.5 x ULN
+Alkaline phosphatase =< 2.5 x the upper normal limit
+Serum alkaline phosphatase level >= 300 IU/L.
+Alkaline phosphatase =< 2.5 X upper limit of normal; in patients with bone metastasis and no evidence of liver metastasis and bilirubin =< upper limit of normal an alkaline phosphatase =< 5 ULN will be allowed
+Alkaline phosphatase ? 2.5 x ULN
+Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
+Alkaline phosphatase < 5 x ULN
+Alkaline phosphatase =< 2.5 x upper limit of normal
+Alkaline phosphatase < 3 times the upper limit of normal (alkaline phosphatase and aspartate aminotransferase [AST] cannot both exceed the upper limit of normal)
+Alkaline phosphatase < 4 x ULN
+Alkaline phosphatase =< 1.5 x ULN
+Alkaline phosphatase (ALP) must be < 2 times the upper limit of normal
+Alkaline phosphatase < 2 x ULN
+Alkaline phosphatase < 5 x upper limit of normal
+For patients with known bone metastases, alkaline phosphatase < 5 x ULN is acceptable
+Alkaline phosphatase =< 1.5 x institutional upper limit of normal (ULN)
+Alkaline phosphatase < 2 x ULN
+Alkaline phosphatase (ALK) =< 1.5 x upper limit of normal (ULN)
+Liver alkaline phosphatase =< 3 x upper limit of normal
+Alkaline phosphatase < 2.5 x the upper limit of normal
+Alkaline phosphatase =< 1.5 x institutional ULN
+Alkaline phosphatase within institutional limits of normal or judged to be not clinically significant by the investigator
+Alkaline phosphatase > 2.5 x ULN
+Alkaline phosphatase < 2.5 x ULN
+Alkaline phosphatase =< 1.5 x upper limit of institutional normal
+Alkaline phosphatase =< 2.5 time ULN
+Alkaline phosphatase =< 1.5 x institutional upper limit of normal
+Obtained within 28 days prior to registration: Alkaline phosphatase =< 2.5 x ULN (subjects with documented liver or bone metastases should have alkaline phosphatase =< 5 x ULN)
+Alkaline phosphatase < 2.5 × ULN unless hepatic metastases are present, then < 5 × ULN
+Alkaline phosphatase =< 2 X ULN
+Alkaline phosphatase (ALP) > 2.5 x ULRR
+Alkaline phosphatase =< 2.5 x IULN
+Alkaline phosphatase (ALK phos) within 2 x ULN
+Alkaline phosphatase =< 2.5 x IULN
+Individuals with alkaline phosphatase (ALP) > 2.5 x normal upper limit any time during the previous 2 months
+Alkaline phosphatase (AP) =< 3 X ULN, obtained within 14 days prior to PET scan
+Serum glutamic-oxaloacetic transaminase (SGOT) and alkaline phosphatase less than or equal to 2.5 x ULN
+Gamma-glutamyl transpeptidase (GGT) > 2.5 x ULN if alkaline phosphatase > 2.5 x ULN obtained < 2 weeks prior to study enrollment
+Gamma-glutamyl transferase (GGT) > 2.5 x ULN IF alkaline phosphatase > 2.5 x ULN
+Alkaline phosphatase must be less than 4 x upper limit of normal
+Gamma glutamyl transpeptidase (GGT) > 2.5 x ULN IF alkaline phosphatase > 2.5 x ULN
+Alkaline phosphatase (ALK phos) less than 4.0 times below or above the upper or lower limit range
+Gamma-Glutamyl Transpeptidase (GGT) > 2.5 x ULN IF alkaline phosphatase > 2.5 x ULN
+Alkaline phosphatase (ALK phos) less than 4.0 times below or above the upper or lower limit range
+Alkaline phosphatase =< 2 times the upper limit of normal
+Gamma glutamyl transferase (GGT) > 2.5 x ULN IF alkaline phosphatase > 2.5 x ULN
+Alkaline phosphatase =< 2.5 x upper limits of normal if no liver metastases present; alkaline phosphatase =< 5 x upper limits of normal if liver metastases present
+Alkaline phosphatase =< 2.5 x ULN in the absence of known bone metastases or =< 5.0 x ULN in the case of bone metastases
+Alkaline phosphatase < 3 x ULN
+Alkaline phosphatase =< 5 x ULN
+Alkaline phosphatase < 2.5 x ULN
+Alkaline phosphatase =< 190 IU/dL
+Patients with plasma alkaline phosphatase greater than 190 IU/dL
+Alkaline phosphatase within normal limits
+Alkaline phosphatase (Alk phos) =< 2.5 X institutional upper limit of normal
+Direct bilirubin ? 1.5 x ULN except for i) patients with documented Gilbert's syndrome for whom any bilirubin value is allowed and ii) for patients with asymptomatic hyperbilirubinemia (liver transaminases and alkaline phosphatase within normal range).
+Alkaline phosphatase ? 2.5 x ULN
+Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ?3 × ULN (?5 × ULN if participant has liver metastases). If alkaline phosphatase is >3 × ULN (in absence of liver metastases) or >5 × ULN (in presence of liver metastases) AND the participant also is known to have bone metastases, the liver-specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of total alkaline phosphatase.